Literature DB >> 6575386

Kinetic analysis of the interaction of human tissue kallikrein with single-chain human high and low molecular weight kininogens.

M Maier, K F Austen, J Spragg.   

Abstract

Human low molecular weight kininogen (LMWK) and high molecular weight kininogen (HMWK) have been purified to apparent homogeneity as intact, single-chain molecules. When they interacted with homologous urinary kallikrein, 0.9 mol of kinin per mol of substrate was released from LMWK and 0.7 mol of kinin per mol of substrate was released from HMWK. These functionally and structurally intact substrates have been used to obtain the kinetic constants for kinin release by purified human tissue kallikreins. With human urinary kallikrein, apparent second-order rate constants (kcat/Km) of 1.46 X 105, 8.6 X 104, and 5.08 X 104 M-1.S-1 were obtained with LMWK, HMWK, and alpha-N-p-tosyl-L-arginine methyl ester (TAMe), respectively; with human pancreatic kallikrein, values of 8.7 X 103 and 7.3 X 104 M-1.S-1 were obtained with HMWK and TAMe. These values, which are comparable to those obtained for other enzyme-protein substrate interactions, indicate that LMWK is only slightly preferred to interactions, indicate that LMWK is only slightly preferred to HMWK as the natural substrate for urinary kallikrein and that HMWK as the natural substrate for urinary kallikrein and that HMWK is a somewhat better substrate for urinary kallikrein than for pancreatic kallikrein. Although the data obtained have been shown by NaDodSO4/polyacrylamide gel electrophoresis to reflect cleavage of the substrate at two points, the linear Line-weaver-Burk plots suggest that one cleavage is rate limiting. Because the plasma concentrations of both LMWK and HMWK are approximately 1/10th the Km values obtained, substrate concentration may also play a role in determining the rate at which tissue kallikreins release kinins from kininogen substrates either in the circulation or extravascularly.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6575386      PMCID: PMC394172          DOI: 10.1073/pnas.80.13.3928

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Bovine plasma HMW and LMW kininogens. Structural differences between heavy and light chains derived from the kinin-free proteins.

Authors:  H Kato; Y N Han; S Iwanaga; T Suzuki; M Komiya
Journal:  J Biochem       Date:  1976-12       Impact factor: 3.387

2.  Flaujeac factor deficiency. Reconstitution with highly purified bovine high molecular weight-kininogen and delineation of a new permeability-enhancing peptide released by plasma kallikrein from bovine high molecular weight-kininogen.

Authors:  R T Matheson; D R Miller; M J Lacombe; Y N Han; S Iwanaga; H Kato; K D wuepper
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

3.  Characterization and localization of human renal kininogen.

Authors:  D Proud; M Perkins; J V Pierce; K N Yates; P F Highet; P L Herring; M Mangkornkanok/Mark; R Bahu; F Carone; J J Pisano
Journal:  J Biol Chem       Date:  1981-10-25       Impact factor: 5.157

4.  Human high molecular weight kininogen. Effects of cleavage by kallikrein on protein structure and procoagulant activity.

Authors:  S Schiffman; C Mannhalter; K D Tyner
Journal:  J Biol Chem       Date:  1980-07-10       Impact factor: 5.157

5.  the preparation of human kininogen. II. Further characterization of purified human kininogen.

Authors:  J Spragg; K F Austen
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

6.  Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.

Authors:  R W Colman; A Bagdasarian; R C Talamo; C F Scott; M Seavey; J A Guimaraes; J V Pierce; A P Kaplan
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

7.  Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein.

Authors:  K Mori; S Nagasawa
Journal:  J Biochem       Date:  1981-05       Impact factor: 3.387

8.  A convenient large-scale preparation of high molecular weight kininogen from human plasma.

Authors:  B Dittmann; A Steger; R Wimmer; H Fritz
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1981-07

9.  Immunochemical studies of human high molecular weight kininogen and of its complexes with plasma prekallikrein or kallikrein.

Authors:  D M Kerbiriou; B N Bouma; J H Griffin
Journal:  J Biol Chem       Date:  1980-05-10       Impact factor: 5.157

10.  Characterization of human high molecular weight kininogen. Procoagulant activity associated with the light chain of kinin-free high molecular weight kininogen.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  J Exp Med       Date:  1978-02-01       Impact factor: 14.307

View more
  6 in total

1.  T-kininogenase activity of the rat submandibular gland is predominantly due to the kallikrein-like serine protease antigen gamma.

Authors:  T Berg; I Wassdal; T Mindroiu; K Sletten; G Scicli; O A Carretero; A G Scicli
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

2.  Hydrolysis of somatostatin by human tissue kallikrein after the amino acid pair phe-Phe.

Authors:  D C Pimenta; M A Juliano; L Juliano
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

3.  Kallikrein rK10-induced kinin-independent, direct activation of NO-formation and relaxation of rat isolated aortic rings.

Authors:  I Wassdal; R Hull; V P Gerskowitch; T Berg
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

4.  Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects.

Authors:  S C Christiansen; D Proud; C G Cochrane
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

5.  Urinary kallikrein excretion during inhibition of endogenous angiotensin II in the pig.

Authors:  B R Binder; M Maier; H Rana; M Starlinger; Z Zhegu
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

6.  Evaluation of the extent of the binding site in human tissue kallikrein by synthetic substrates with sequences of human kininogen fragments.

Authors:  E Del Nery; J R Chagas; M A Juliano; E S Prado; L Juliano
Journal:  Biochem J       Date:  1995-11-15       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.